Welcome to our dedicated page for Definium Therapeutics SEC filings (Ticker: DFTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Definium Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Definium Therapeutics's regulatory disclosures and financial reporting.
Daniel Rollings Karlin submitted a notice under Form 144 relating to Common stock held with Morgan Stanley Smith Barney LLC Executive Financial Services. The notice lists 10,035 shares tied to restricted stock vesting under a registered plan with a 06/25/2026 date. The filing also records 8,018 shares sold during the past three months on 03/25/2026.
DFTX submitted a Form 144 notice to sell 29,208 shares of Common Stock in connection with restricted stock vesting under a registered plan, with the transaction date listed as 06/25/2026. The filing also reports a prior sale of 24,431 shares on 03/25/2026 for $451,240.57, attributed to Robert B. Barrow. The sale reason is listed as Services Rendered.
Definium Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 20,588,236 common shares at $34.00 per share, plus an additional 3,088,235 shares under a 30‑day option that was exercised in full. Including this option, gross proceeds are expected to be about $805 million, with net proceeds of approximately $758 million after underwriting discounts, commissions, and estimated expenses. The company plans to use the cash to fund research and development, prepare for potential commercialization of DT120 ODT if approved, and for working capital and general corporate purposes. Directors and executives agreed to a 60‑day lock‑up restricting share sales without underwriter consent.
Definium Therapeutics, Inc. is conducting a registered underwritten public offering of 20,588,236 common shares at a public offering price of $34.00 per share, for gross proceeds of $700,000,024. Delivery of the common shares is expected on or about June 25, 2026. The underwriters have a 30-day option to purchase up to an additional 3,088,235 common shares at the same public offering price less underwriting discounts and commissions.
The company estimates net proceeds to Definium of approximately $659.0 million (or approximately $758.0 million if the option is exercised in full). Definium intends to use proceeds for research and development of product candidates, preparation activities for potential commercialization of DT120 ODT if approved, and working capital and general corporate purposes.
Definium Therapeutics, Inc. is offering $500,000,000 of common shares and pre-funded warrants pursuant to a preliminary prospectus supplement dated June 22, 2026 (subject to completion). The shares trade on Nasdaq under DFTX; the last reported sale price on June 18, 2026 was $24.48 per share.
The prospectus supplement relates to a primary shelf offering of common shares and pre-funded warrants, and discloses pro forma share counts including 104,044,508 common shares outstanding as of March 31, 2026. The offering includes a 30-day underwriter option to purchase up to an additional $75,000,000 of common shares. The supplement also summarizes recent clinical developments: the Phase 3 Emerge study in MDD met its primary and key secondary endpoints (MADRS LS mean change at Week 6: -13.3 for DT120 100 µg vs -5.2 for placebo; placebo-adjusted difference -8.1, p<0.0001).
Wiley Matthew T. reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Commercial Officer Matthew T. Wiley received an award of 62,500 common shares at no purchase price as part of his equity compensation. After this grant, he directly holds 177,500 common shares.
According to the footnote, these shares represent the first tranche of performance share units granted effective March 17, 2025. They remain subject to vesting based on his continued employment through March 17, 2028 and achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement.
Barrow Robert reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Executive Officer Robert Barrow received a grant of 375,000 common shares as a stock award, with no cash paid per share. Following this award, he directly holds 1,127,454 common shares.
The shares represent the first tranche of performance share units originally granted effective March 12, 2025. They remain subject to vesting based on his continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones.
Roberts Brandi reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. Chief Financial Officer Brandi Roberts reported an equity compensation grant of 62,500 common shares at a price of $0.00 per share. These shares represent the first tranche of performance share units granted effective June 2, 2025.
The units remain subject to vesting based on her continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones in the Performance Share Unit Award Agreement. Following this award, Roberts directly holds 212,500 common shares.
Sullivan Mark reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics Chief Legal Officer Mark Sullivan received 62,500 common shares as a performance-based equity award. The shares were granted at no purchase price and increase his direct holdings to 333,579 common shares. This tranche stems from performance share units granted effective March 12, 2025 and remains subject to vesting based on continued employment through March 12, 2028 and achievement of specified clinical and regulatory milestones.
Definium Therapeutics, Inc. reported that Chief Medical Officer Karlin Daniel received an award of 100,000 common shares at a price of $0.00 per share, classified as a grant or award acquisition. Following this transaction, he directly holds 513,317 common shares.
According to the footnote, these common shares represent the first tranche of performance share units granted effective March 12, 2025. They remain subject to vesting based on Daniel’s continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement.